The complete research guide to TB-500 (thymosin beta-4 fragment 17-23) — TB4 vs TB-500 comparisons, dosage protocols, mechanism of action, and the latest scientific research
TB4 is the full protein; TB-500 is the fragment built from it. Thymosin Beta-4 (TB4, Tβ4) is a naturally occurring 43-amino acid protein present in nearly every cell in the body. TB-500 is a synthetic 7-amino acid peptide — amino acids 17-23 of that protein — manufactured because it carries the actin-binding activity researchers care about, without the cost of producing the full-length molecule.
They are related, not identical. TB-500 shares TB4's core actin-regulation mechanism, but not every downstream effect attributed to full-length TB4 has been demonstrated for the fragment specifically — and because "TB-500" is a commercial name rather than a standardized one, some suppliers use it loosely for either molecule. If you're comparing the two for research purposes, the sequence on the certificate of analysis matters more than the name on the label.
Read the Full TB-500 vs TB4 Comparison →Information grounded in published studies on thymosin beta-4 and its synthetic fragments, referencing real scientific literature.
Detailed breakdowns of loading phases, maintenance protocols, reconstitution guides, and administration methods used in research.
Honest safety profiles, side effect research, and head-to-head comparisons with other peptides like BPC-157.
TB-500 vs MOTS-c compared from the primary literature: where each peptide comes from, what they do (actin and cell migration vs the folate-AMPK metabolic pathway), the CB4211 human data, WADA status, and the July 2026 FDA advisory votes.
TB-500 vs LL-37 compared from the primary literature: where each peptide comes from, how they act (actin sequestration vs antimicrobial and immune signaling), what the venous leg ulcer trials of LL-37 actually found, safety signals, and 2026 FDA compounding status.
Ac-SDKP is the N-terminal tetrapeptide of thymosin beta-4 and TB-500 is the 17-23 actin-binding fragment. How each is made, what the primary literature reports (hematopoiesis, fibrosis, ACE), why a TB-500 vial cannot produce Ac-SDKP, and what that means for research design.
Why research-grade TB-500 and thymosin beta-4 are sold as trifluoroacetate (TFA) or acetate salts, what the peer-reviewed counter-ion literature says about TFA in cell assays, how salt form changes net peptide content, and what to look for on a COA.
Human thymosin beta-4 (UniProt P62328) is a 43-residue intrinsically disordered peptide with an AcSDKP N-terminus and LKKTET actin-binding motif. How that sequence relates to research-grade TB-500 fragments, PDB actin-bound structures, and what sequence identity on a COA actually means.
Does TB-500 cause cancer? A source-by-source read of the thymosin beta-4 tumor literature: melanoma, colorectal, and pancreatic studies pointing one way, multiple myeloma pointing the other, and why none of it measures injected peptide in humans.
No. Thymosin Beta-4 (TB4 or Tβ4) is the full 43-amino acid protein made naturally in nearly every human and animal cell. TB-500 is a synthetic peptide built from just the active fragment of that protein — amino acids 17-23, the region responsible for actin binding. TB-500 is derived from TB4 and shares its core mechanism, but the two are not interchangeable in size, research history, or (in some cases) what a vendor actually ships in the vial. See our full breakdown for the exact differences.
TB-500 is a synthetic peptide fragment of thymosin beta-4 (Tβ4), a naturally occurring 43-amino acid protein found in nearly all human and animal cells. It plays a key role in tissue repair, cell migration, and inflammation regulation. TB-500 specifically consists of the active region of Tβ4 (amino acids 17-23) responsible for actin binding and cell motility.
TB-500 works primarily by upregulating actin, a cell-building protein essential for tissue repair. It promotes angiogenesis (new blood vessel formation), reduces inflammation, and enhances cell migration to injury sites. Research suggests it activates satellite cells in muscle tissue and promotes keratinocyte migration for wound healing.
While both are healing peptides, they work through different mechanisms. TB-500 primarily promotes systemic healing through actin regulation and cell migration, while BPC-157 works locally through growth factor modulation and gut-healing properties. Many researchers study them in combination for synergistic effects.
TB-500 is legal to purchase as a research chemical in most countries. However, it is banned by WADA (World Anti-Doping Agency) and most sports organizations. It is not approved by the FDA for human use. Always check your local regulations before purchasing.
Published research in journals like the Annals of the New York Academy of Sciences and FASEB Journal has shown thymosin beta-4 promotes wound healing, reduces inflammation, and supports cardiac tissue repair in animal models. The peptide has demonstrated promise for tendon, ligament, muscle, and skin repair in preclinical studies.
The buy guide covers vendor checks, COAs, and red flags. It links to a real research-peptide source. TB-500 is not FDA-approved for human use and is sold for laboratory research only.
Read Where to Buy TB-500 →New dosage guides, study breakdowns, and protocol updates — delivered to your inbox. No spam, unsubscribe anytime.